Comparative Pharmacology
Head-to-head clinical analysis: LEQEMBI versus SOLIRIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEQEMBI versus SOLIRIS.
LEQEMBI vs SOLIRIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lecanemab is a humanized monoclonal antibody that targets aggregated soluble and insoluble forms of amyloid beta, reducing amyloid plaques in the brain.
Soliris (eculizumab) is a monoclonal antibody that specifically binds to complement protein C5, thereby inhibiting its cleavage to C5a and C5b and preventing the formation of the membrane attack complex (MAC). This action blocks terminal complement-mediated inflammation and cell lysis.
10 mg/kg intravenously every 2 weeks, administered over approximately 1 hour.
600 mg intravenous over 35 minutes weekly for 4 weeks, then 900 mg 1 week later, followed by 900 mg every 2 weeks for paroxysmal nocturnal hemoglobinuria (PNH). For atypical hemolytic uremic syndrome (aHUS): 900 mg intravenous over 35 minutes weekly for 4 weeks, then 1200 mg 1 week later, followed by 1200 mg every 2 weeks.
None Documented
None Documented
Terminal half-life approximately 7.6 days (range 5-12 days) after multiple doses; supports monthly dosing.
Terminal elimination half-life: approximately 11.3 ± 3.4 days (range 8–18 days) following biweekly dosing. This supports a dosing interval of every 2 weeks for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Primarily catabolized to amino acids; not excreted renally or hepatically in unchanged form.
Eculizumab is not metabolized by cytochrome P450 enzymes; it is degraded via general protein catabolism. Clearance is primarily through the reticuloendothelial system; renal excretion of intact drug is negligible (<1%). No biliary or fecal excretion data are available in humans.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody